The operative risk factors in the metabolic syndrome: Is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity?

Current Diabetes Reports

Volumn 7, Issue 1, 2007, Pages 74-81

  Martens, Fabrice M A C ^a   Visseren, Frank L J ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAMIPRIL; ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; AGING; ATHEROGENESIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG SCREENING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE CLAMP TECHNIQUE; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; THROMBOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD PRESSURE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY; RISK FACTORS;

EID: 33847373023     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0013-7     Document Type: Review

References (65)

1. Stevens RJ, Coleman RL, Adler AI, et al.: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004, 27:201-207.
2. Turner RC: The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998, 21(suppl 3):C35-C38.
3. Caballero AE: Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 2005, 36:241-249.
4. Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
5. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
6. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
7. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442-443.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2497.
9. Einhorn D, Reaven GM, Cobin RH, et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9:237-252.
10. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
11. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
12. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al.: Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 2004, 147:106-112.
13. Marques-Vidal P, Mazoyer E, Bongard V, et al.: Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002, 25:1371-1377.
14. Gorter PM, Olijhoek JK, van der GY, et al.: Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004, 173:363-369.
15. Hanley AJ, Karter AJ, Williams K, et al.: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosderosis Study. Circulation 2005, 112:3713-3721.
16. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
17. Hu G, Qiao Q, Tuomilehto J, et al.: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066-1076.
18. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
19. Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004, 173:309-314.
20. Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosderosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141.
21. Hunt KJ, Resendez RG, Williams K, et al.: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004, 110:1251-1257.
22. Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
23. Dekker JM, Girman C, Rhodes T, et al.: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112:666-673.
24. Bonora E, Kiechl S, Willeit J, et al.: Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003, 26:1251-1257.
25. Olijhoek JK, van der Graaf Y, Banga JD, et al.: The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348.
26. Schillaci G, Pirro M, Vaudo G, et al.: Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005, 45:1078-1082.
27. Saely CH, Koch L, Schmid F, et al.: Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006, 29:901-907.
28. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195-1200.
29. Scuteri A, Najjar SS, Muller DC, et al.: Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004, 43:1388-1395.
30. Wilson PW: Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004, 33:467-481.
31. Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004, 33:283-303.
32. Sakkinen PA, Wahl P, Cushman M, et al.: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897-907.
33. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000, 20:2140-2147.
34. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
35. Yusuf S, Hawken S, Ounpuu S, et al.: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
36. Jazet IM, Pijl H, Meinders AE: Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003, 61:194-212.
37. Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995, 44:1038-1045.
38. Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(suppl 3):14-23.
39. Ginsberg HN, Huang LS: The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000, 7:325-331.
40. Feinstein R, Kanety H, Papa MZ, et al.: Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
41. Ridker PM, Rifai N, Pfeffer M, et al.: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149-2153.
42. Martens FM, Rabelink TJ, op 't Roodt J, et al.: TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 2006, 27:1605-1609.
43. Stefan N, Vozarova B, Funahashi T, et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
44. Tschritter O, Fritsche A, Thamer C, et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52:239-243.
45. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
46. Steinberg HO, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia 2002, 45:623-634.
47. Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255-268.
48. Chait A, Brazg RL, Tribble DL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94:350-356.
49. Ashley FW Jr, Kannel WB: Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chronic Dis 1974, 27:103-114.
50. Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992, 20:38-45.
51. Rocchini AP, Key J, Bondie D, et al.: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989, 321:580-585.
52. Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 2000, 101:329-335.
53. Modan M, Halkin H, Almog S, et al.: Hyperinsulinemia. A link between hypertension obesity and glucose intolerance J Clin Invest 1985, 75:809-817.
54. Falloon BJ, Heagerty AM: In vitro perfusion studies of human resistance artery function in essential hypertension. Hypertension 1994, 24:16-23.
55. Rizzoni D, Porteri E, Castellano M, et al.: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996, 28:785-790.
56. Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
57. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148:209-214.
58. Chia S, Qadan M, Newton R, et al.: Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003, 23:695-701.
59. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
60. Blake GJ, Ridker PM: C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002, 22:1512-1513.
61. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
62. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006, 368:919-928.
63. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
64. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
65. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.